Francesco Onida, Luuk Gras, Junran Ge, Linda Koster, Rose-Marie Hamladji, Jenny Byrne, Daniele Avenoso, Mahmoud Aljurf, Marie Robin, Kazimierz Halaburda, Jakob Passweg, Urpu Salmenniemi, Henrik Sengeloev, Jane Apperley, Andrew Clark, Péter Reményi, Elena Morozova, Francesca Kinsella, Stig Lenhoff, Arnold Ganser, Ka Lung Wu, Antonio Perez-Martinez, Patrick J Hayden, Kavita Raj, Joanna Drozd-Sokolowska, Guillermo OrtÍ, Hugues de Lavallade, Ibrahim Yakoub-Agha, Donal P McLornan, Yves Chalandon
Allogeneic haematopoietic cell transplantation (allo-HCT) remains an option for tyrosine kinase inhibitor-resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high-risk patients with advanced disease phases. In this European Society for Blood and Marrow Transplantation (EBMT) registry-based study of 1686 CML patients undergoing first allo-HCT between 2012 and 2019, outcomes were evaluated according to donor type, particularly focusing on mismatched related donors (MMRDs). Median age at allo-HCT was 46 years (IQR 36-55)...
April 5, 2024: British Journal of Haematology